Critical Path Trickles Downstream To FDA Reviewers
Executive Summary
A lack of interest from agency review staff impedes progress of FDA's Critical Path Initiative, industry members observe
You may also be interested in...
FDA Should Look Through IIRIS To Improve Science, Panel Says; Funding Is Worry
Increasing developments in emerging sciences, such as personalized medicine, could reach roadblocks at FDA where limited resources for specialized personnel and advanced equipment may inhibit research, a report from FDA's Science Board's Subcommittee on Science and Technology shows
“Critical Path” Is On The Road Forward; FDA Reports Industry Activity Is High
The Critical Path Initiative is entering 2007 with growing momentum, bolstered by a new, tailored agency infrastructure and increased industry awareness of FDA's initiative to spur drug development
FCPA In The China Framework Warrants Special Attention
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?